Keyword search (4,163 papers available)

"Chertkow H" Authored Publications:

Title Authors PubMed ID
1 Basic Science and Pathogenesis Borrie MJ; Phillips NA; Best S; Anastasiou-Ventura P; Aydogan T; Beaudoin C; Beuk J; Celotto I; Cole L; Das S; Fogarty J; Fouquet C; Gnassi L; Henri-Bellemare C; Pilon R; Sands J; Stirbu A; Truemner J; Chan S; Tucker A; Gajraj J; Bhangu J; Chertkow H; 41435411
CONCORDIA
2 Public Health Gurve D; Centen AP; Slack PJ; Dang-Vu TT; Belleville S; Anderson ND; Montero-Odasso M; Nygaard HB; Chertkow H; Feldman HH; Brewster PWH; Lim A; 41434309
PERFORM
3 Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H; 41358624
PSYCHOLOGY
4 Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; 39893139
CONCORDIA
5 Basic Science and Pathogenesis Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H; 39751468
CONCORDIA
6 Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; 39636028
HKAP
7 A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H; 37182684
PERFORM
8 Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab Chertkow H; Rockwood K; Hogan DB; Phillips N; Montero-Odasso M; Amanullah S; Black S; Bocti C; Borrie M; Feldman H; Freedman M; Hsiung R; Kirk A; Masellis M; Nygaard H; Rajji T; Verret L; 34912492
PSYCHOLOGY
9 Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants 32725777
PERFORM
10 Clinical judgement is paramount when performing cognitive screening during COVID-19. Phillips NA, Andrews M, Chertkow H, Pichora-Fuller MK, Rockwood K, Wittich W 32396983
PSYCHOLOGY
11 Special issues on using the MoCA for remote assessment during COVID-19 2. Phillips NA, Chertkow H, Pichora-Fuller MK, Wittich W 32253754
PSYCHOLOGY
12 The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ 31309917
PSYCHOLOGY
13 Functional and anatomical memory indices in patients with or at risk for Alzheimer's disease. Phillips NA, Chertkow H, Leblanc MM, Pim H, Murtha S 15012840
PSYCHOLOGY

 

Title:Basic Science and Pathogenesis
Authors:Lima BSRosa-Neto PPhillips NBorrie MRoncero CTLahiri DDori DChertkow H
Link:https://pubmed.ncbi.nlm.nih.gov/39751468/
DOI:10.1002/alz.090393
Publication:Alzheimer s & dementia : the journal of the Alzheimer s Association
Keywords:
PMID:39751468 Category: Date Added:2025-01-03
Dept Affiliation: CONCORDIA
1 Rotman Research Institute, Toronto, ON, Canada.
2 Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.
3 Concordia University, Montreal, QC, Canada.
4 Division of Geriatric Medicine, Western University, London, ON, Canada.
5 Baycrest/Rotman Research Institute, Toronto, ON, Canada.
6 Rotman Research Institute-Baycrest, TORONTO, ON, Canada.
7 Canadian Consortium on Neurodegeneration in Aging (CCNA), Montreal, QC, Canada.

Description:

Background: A growing body of research has focused on inflammation as both a potential biomarker and a risk factor for Alzheimer's disease (AD). The cytokine Interleukin-6 (IL-6) is involved in the pathogenesis of inflammatory disorders and in the physiological homeostasis of neural tissue. AD has been associated with increased IL-6 expression in brain, however, increased levels of IL-6 have also been linked to conditions such as diabetes and hypertension. We examined groups of individuals with AD and related disorders (ADRD) as well as healthy controls to check if elevated levels of IL-6 (above 1.9 ng/L) were related to the presence of comorbidities.

Methods: We investigated individuals with AD (n = 58); mild cognitive impairment (MCI; n = 139); subjective cognitive impairment (SCI; n = 28); and cognitively unimpaired age matched controls (CU; n = 53). We considered four possible subgroups: Group 0 (defined as individuals with normal IL-6 levels and without comorbidities that could be linked to elevated IL-6); Group 1 (individuals with normal levels of IL-6, despite having comorbidities); Group 2 (individuals with elevated IL-6 without comorbidities), and Group 3 (individuals with elevated IL-6 and comorbidities). The comorbidities investigated were hypertension, diabetes, peripheral vascular disease, history of cerebrovascular accident, and rheumatoid arthritis. Logistic regression was used to investigate the relationship between the occurrence of elevated IL-6, age, sex, history of smoking, body mass index (BMI), Montreal Cognitive Assessment scores (MoCA), nutrition and sleep.

Results: We found individuals with and without elevated IL-6, and with and without comorbidities in all cohorts (Table 1). We found a significant relationship between elevated IL-6 and aging in all cohorts (Figure 1a). A significant relationship was also found between elevated IL-6 and greater BMI (MCI group only; Figure 1b), lower nutrition scores (SCI group only, Figure 1c), history of smoking (AD group only; Figure 2a) and sex, whereby males had more elevated IL-6 (MCI group; Figure 2b).

Conclusions: We found variation in patterns of peripheral inflammation and other common conditions in aging and ADRD. These variations may reflect different mechanistic groups which might help the understanding of variation in clinical features of ADRD, disease progression and response to different therapeutic interventions.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University